445.30MMarket Cap-4329P/E (TTM)
8.790High7.330Low240.96KVolume8.790Open8.800Pre Close1.89MTurnover0.92%Turnover RatioLossP/E (Static)55.59MShares10.25052wk High-15.74P/B209.44MFloat Cap2.70052wk Low--Dividend TTM26.15MShs Float28.265Historical High--Div YieldTTM16.59%Amplitude2.700Historical Low7.825Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet